Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
Windtree Therapeutics has announced the appointment of Leanne Kelly to its Board of Directors. Ms. Kelly, who will serve as an independent director and chair of the audit committee, brings over 20 years of public company executive experience. She is currently the Chief Financial Officer at GRI Bio and has previously held significant roles at Vallon Pharmaceuticals, OptiNose, Flower Orthopedics, Iroko Pharmaceuticals, and Genaera Ms. Kelly holds a degree in business economics with a concentration in accounting from Lehigh University and is a licensed CPA (inactive) in Pennsylvania.
Windtree's CEO, Jed Latkin, expressed excitement about Ms. Kelly's addition, highlighting her expertise as a valuable asset to the board. This appointment aligns with Windtree's new corporate strategy aimed at transforming into a revenue-generating biotechnology company. The strategy involves using company equity to acquire small biotech firms with FDA-approved products that have yet to realize their full commercial potential.
Windtree Therapeutics ha annunciato la nomina di Leanne Kelly nel suo Consiglio di Amministrazione. La signora Kelly, che ricoprirà il ruolo di direttore indipendente e presidente del comitato per la revisione contabile, porta con sé oltre 20 anni di esperienza nell'ambito di aziende pubbliche. Attualmente è il Chief Financial Officer di GRI Bio e ha ricoperto ruoli significativi in Vallon Pharmaceuticals, OptiNose, Flower Orthopedics, Iroko Pharmaceuticals e Genaera. La signora Kelly ha conseguito una laurea in economia aziendale con specializzazione in contabilità presso la Lehigh University ed è un CPA (inattivo) licenziato in Pennsylvania.
Il CEO di Windtree, Jed Latkin, ha espresso entusiasmo per l'aggiunta della signora Kelly, sottolineando come la sua esperienza rappresenti un prezioso patrimonio per il consiglio. Questa nomina si allinea con la nuova strategia societaria di Windtree, mirata a trasformarsi in una compagnia biotecnologica generatrice di entrate. La strategia prevede l'utilizzo del capitale aziendale per acquisire piccole aziende biotecnologiche con prodotti approvati dalla FDA che devono ancora realizzare il loro pieno potenziale commerciale.
Windtree Therapeutics ha anunciado el nombramiento de Leanne Kelly en su Consejo de Administración. La Sra. Kelly, quien servirá como directora independiente y presidenta del comité de auditoría, aporta más de 20 años de experiencia ejecutiva en empresas públicas. Actualmente es la Directora Financiera de GRI Bio y ha ocupado anteriormente roles significativos en Vallon Pharmaceuticals, OptiNose, Flower Orthopedics, Iroko Pharmaceuticals y Genaera. La Sra. Kelly tiene un título en economía empresarial con concentración en contabilidad de la Lehigh University y es CPA (inactiva) licenciada en Pennsylvania.
El CEO de Windtree, Jed Latkin, expresó su entusiasmo por la incorporación de la Sra. Kelly, destacando que su experiencia es un activo valioso para el consejo. Este nombramiento se alinea con la nueva estrategia corporativa de Windtree, que busca transformarse en una empresa biotecnológica generadora de ingresos. La estrategia implica usar el capital de la empresa para adquirir pequeñas empresas biotecnológicas con productos aprobados por la FDA que aún no han alcanzado su pleno potencial comercial.
Windtree Therapeutics는 Leanne Kelly을 이사회의 새로운 멤버로 임명했다고 발표했습니다. Kelly 씨는 독립 이사이자 감사위원회 의장으로 활동하며, 20년 이상의 공기업 경영 경험을 보유하고 있습니다. 현재 GRI Bio의 최고 재무 책임자(CFO)로 재직 중이며, 과거 Vallon Pharmaceuticals, OptiNose, Flower Orthopedics, Iroko Pharmaceuticals, Genaera에서 중요한 역할을 맡았습니다. Kelly 씨는 Lehigh University에서 회계에 중점을 둔 경영경제학 학위를 취득했으며, 펜실베니아주에서 비활성 CPA 자격증을 보유하고 있습니다.
Windtree의 CEO인 Jed Latkin은 Kelly 씨의 합류에 대한 기대감을 표명하며, 그녀의 전문성이 이사회에 매우 귀중한 자산이 될 것이라고 강조했습니다. 이 임명은 Windtree의 수익 창출 생명공학 회사로의 전환을 목표로 하는 새로운 기업 전략과 일치합니다. 이 전략은 FDA 승인 제품을 보유한 작은 생명공학 회사를 인수하는 데 회사 자본을 사용하는 것을 포함합니다.
Windtree Therapeutics a annoncé la nomination de Leanne Kelly au sein de son Conseil d'Administration. Mme Kelly, qui exercera en tant que directrice indépendante et présidente du comité d'audit, apporte plus de 20 ans d'expérience à des postes exécutifs dans des entreprises publiques. Elle est actuellement Directrice Financière chez GRI Bio et a précédemment occupé des rôles significatifs chez Vallon Pharmaceuticals, OptiNose, Flower Orthopedics, Iroko Pharmaceuticals et Genaera. Mme Kelly est titulaire d'un diplôme en économie d'entreprise avec une spécialisation en comptabilité de la Lehigh University et est une CPA (inactive) licenciée en Pennsylvanie.
Le CEO de Windtree, Jed Latkin, a exprimé son enthousiasme quant à l'ajout de Mme Kelly, soulignant que son expertise constitue un atout précieux pour le conseil. Cette nomination s'inscrit dans la nouvelle stratégie d'entreprise de Windtree, visant à se transformer en une entreprise de biotechnologie générant des revenus. La stratégie implique d'utiliser le capital de l'entreprise pour acquérir de petites entreprises biopharmaceutiques avec des produits approuvés par la FDA qui n'ont pas encore réalisé leur plein potentiel commercial.
Windtree Therapeutics hat die Ernennung von Leanne Kelly in ihren Verwaltungsrat bekannt gegeben. Frau Kelly wird als unabhängige Direktorin und Vorsitzende des Prüfungsausschusses tätig sein und bringt über 20 Jahre Erfahrung in öffentlichen Unternehmen mit. Derzeit ist sie Chief Financial Officer bei GRI Bio und hatte zuvor bedeutende Positionen bei Vallon Pharmaceuticals, OptiNose, Flower Orthopedics, Iroko Pharmaceuticals und Genaera inne. Frau Kelly hat einen Abschluss in Betriebswirtschaft mit Schwerpunkt Rechnungswesen von der Lehigh University und ist ein lizenziertes CPA (inaktiv) in Pennsylvania.
Der CEO von Windtree, Jed Latkin, äußerte seine Begeisterung über den Zugang von Frau Kelly und hob hervor, dass ihre Expertise einen wertvollen Beitrag für den Vorstand leistet. Diese Ernennung steht im Einklang mit Windtrees neuer Unternehmensstrategie, die darauf abzielt, sich in ein umsatzgenerierendes Biotechnologieunternehmen zu verwandeln. Die Strategie beinhaltet die Verwendung von Unternehmenskapital, um kleine Biotechnologiefirmen mit von der FDA genehmigten Produkten zu erwerben, die noch nicht ihr volles kommerzielles Potenzial ausgeschöpft haben.
- Leanne Kelly's appointment brings over 20 years of valuable public company executive experience.
- Kelly’s background in finance and leadership roles in various biotech and pharmaceutical companies strengthens Windtree's board.
- Her experience is expected to support Windtree's strategy to become a revenue-generating biotech company through acquisitions.
- Potential concerns regarding continuity and gaps in experience within Windtree's existing management team.
WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors (“Board”). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee.
Ms. Kelly has served as GRI Bio’s Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors with a foundation in public accounting. Prior to joining GRI Bio, she most recently served as Chief Financial Officer of Vallon Pharmaceuticals from May 2021 until April 2023. Previously, she was Controller and Executive Director, Global Financial Reporting at OptiNose, Inc. from 2016 to 2021. Over the course of her career, she has held Senior Vice President of Finance, Controller and Chief Financial Officer positions in private and public companies such as Flower Orthopedics from 2013 to 2016, Iroko Pharmaceuticals, LLC in 2013, and Genaera Corporation from 2002 to 2009. Ms. Kelly received her undergraduate degree in business economics with a concentration in accounting from Lehigh University and is a licensed CPA (inactive status) in the state of Pennsylvania.
Jed Latkin, CEO of Windtree said, “We are excited to welcome Leanne to Windtree’s Board of Directors. Her experience will enhance the strength of our Board as we launch our new corporate strategy to become a revenue-generating biotech by using Company equity to acquire small biotech companies struggling to maximize the commercial potential of their FDA-approved products. We look forward to sharing our progress as we execute this strategy.”
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company’s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in Israel and Gaza, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
ecurtis@windtreetx.com
FAQ
Who is the new addition to Windtree's Board of Directors?
What role will Leanne Kelly serve on Windtree's Board?
What is Leanne Kelly's background?
How does Leanne Kelly's appointment impact Windtree's strategy?
What is Windtree's new corporate strategy?
What is Leanne Kelly's educational background?
